Shuo Du,Yunlong Cao,Qinyu Zhu,Pin Yu,Feifei Qi,Guopeng Wang,Xiaoxia Du,Linlin Bao,Wei Deng,Hua Zhu,Jiangning Liu,Jianhui Nie,Yinghui Zheng,Haoyu Liang,Ruixue Liu,Shuran Gong,Hua Xu,Ayijiang Yisimayi,Qi Lv,Bo Wang,Runsheng He,Yunlin Han,Wenjie Zhao,Yali Bai,Yajin Qu,Xiang Gao,Chenggong Ji,Qisheng Wang,Ning Gao,Weijin Huang,Youchun Wang,X Sunney Xie,Xiao-Dong Su,Junyu Xiao,Chuan Qin,X. Sunney Xie,Xiao-dong Su

Abstract:BD-368-2 blocks all three ACE2 binding sites regardless of RBD spatial conformationsBD-368-2 treats severely infected hamsters at low dosages and various dose windowsNew cocktail design based on BD-368-2 neutralizes escaping SARS-CoV-2 mutantsUnderstanding how potent neutralizing antibodies (NAbs) inhibit SARS-CoV-2 is critical for effective therapeutic development. We previously described BD-368-2, a SARS-CoV-2 NAb with high potency; however, its neutralization mechanism is largely unknown. Here we report the 3.5-Å cryo-EM structure of BD-368-2/trimeric-spike complex, revealing that BD-368-2 fully blocks ACE2 recognition by occupying all three receptor-binding domains (RBDs) simultaneously, regardless of their "up" or "down" conformations. Also, BD-368-2 treats infected adult hamsters at low dosages and at various administering windows, in contrast to placebo hamsters that manifested severe interstitial pneumonia. Moreover, BD-368-2's epitope completely avoids the common binding site of VH3-53/VH3-66 recurrent NAbs, evidenced by tripartite co-crystal structures with RBD. Pairing BD-368-2 with a potent recurrent NAb neutralizes SARS-CoV-2 pseudovirus at pM level and rescues mutation-induced neutralization escapes. Together, our results rationalized a new RBD epitope that leads to high neutralization potency and demonstrated BD-368-2's therapeutic potential in treating COVID-19.

What problem does this paper attempt to address?

The paper aims to address the following key issues: 1. **Elucidating the neutralization mechanism of the potent neutralizing antibody BD-368-2**: Using high-resolution cryo-electron microscopy (cryo-EM) and crystallography techniques, the research team resolved the structure of the BD-368-2 in complex with the SARS-CoV-2 spike protein trimer (S trimer). They revealed how BD-368-2 simultaneously occupies all three receptor-binding domains (RBDs), regardless of whether these RBDs are in the "up" or "down" conformation, thereby completely blocking ACE2 recognition. 2. **Evaluating the therapeutic efficacy of BD-368-2 in a severe infection hamster model**: The research team tested the therapeutic efficacy of BD-368-2 in a severely infected adult hamster model. They found that even at different dosing windows (from 24 hours before infection to 48 hours post-infection) and at low doses, BD-368-2 significantly reduced lung inflammation, viral load, and weight loss. 3. **Designing effective antibody cocktail therapies to prevent viral escape**: The research team further explored the combination of BD-368-2 with other potent neutralizing antibodies (such as BD-629 derived from VH3-53/VH3-66). They found that this combination could effectively neutralize wild-type SARS-CoV-2 pseudovirus as well as some natural variants, including L452R, V483A, V483I, and F490L, which are resistant to BD-368-2 alone. By addressing these issues, the research team not only elucidated the potent neutralization mechanism of BD-368-2 but also provided strong evidence for its potential in clinical applications, especially for patients who may develop severe COVID-19. Additionally, the research offers new strategies for developing antibody cocktail therapies that can prevent viral escape.

Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy